We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Long Waits for Defibrillators Increase Mortality

By HospiMedica staff writers
Posted on 25 Jul 2006
Waiting the guideline-mandated three months or nine months required between diagnosis of nonischemic dilated cardiomyopathy (NIDCM) and placement of an implantable cardioverter-defibrillator (ICD) may not be in the best interest of some patients, according to a new study.

Researchers from the Feinberg School of Medicine at Northwestern University (Chicago, IL, USA) analyzed data from the defibrillators in a nonischemic cardiomyopathy treatment evaluation trial that included patients with NIDCM and left ejection fraction of less than 36% and excluded individuals with potentially reversible NIDCM. More...
A total of 458 patients were randomly assigned to standard medical therapy with or without an ICD, regardless of time since diagnosis. The researchers evaluated outcomes as related to time between diagnosis and randomization to ICD treatment or not, with three months and nine months as cut-off points.

When a cut-off point of three months was used, 10.2% of patients with recently diagnosed NIDCM died within the next 2.5 years, whereas among patients who were treated nine months after diagnosis, 11.2% died during the same period. The all-cause mortality rate was 7.3% in those diagnosed within three months of ICD treatment, compared with 15% among those who were treated more than three months after diagnosis. The difference around the nine-month cut-off point was similar: 9.2% mortality before vs 15.6% after. The results were published in the June 20, 2006, issue of the Journal of the American College of Cardiology.

"The primary theoretical reason [for waiting several months] is that there are some people who develop myocarditis who will get better, and because of that concern, people shouldn't get implanted immediately after diagnosis,” said lead author Dr. Alan Kadish. "However, I think this guideline should be reevaluated because, based on the data from this trial and other retrospective studies, there is evidence that some people don't do well if they wait.”

The researchers noted that a task force of experts should develop a list of reversible myopathies for which the need for an ICD would be ruled out, thereby identifying patients who should be treated soon after diagnosis.


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.